Matthew Bending
Matt is the vice president and global head of the Value & Access Consulting team at Evidera, part of PPD clinical research business, Thermo Fisher Scientific. With over 18 years of consulting experience, he has worked on more than 350 market access, health technology assessment (HTA), and health economics and outcomes research (HEOR) projects.
Matt provides senior leadership for large projects on HTA strategy, Integrated Scientific Advice (ISA), and HTA policy for pharmaceutical, vaccine and medical device companies across several disease areas. His experience is wide-ranging, including projects for HTA/multiple HTA scientific advice, parallel and joint regulatory and HTA scientific advice, value proposition development, HTA policy, HTA landscaping, evidence generation gap analysis, evidence synthesis, health economic modeling, and payer advisory boards.
He has held more than 10 ISA roundtable events, presented at international conferences, and published over 35 reports/papers on HTA and HEOR topics. Matt was a co-author of a study on the international harmonization of HTA that won the Egon Jonsson Award in 2009-10 for the most outstanding manuscript published in the International Journal of Technology Assessment in Health Care.
Prior to joining Evidera, Matt developed the early integrated HTA scientific practice in ICON plc. and led the Mapi Group HTA, Strategy and Communication team as senior director with experience of over 65 formal ISA engagements across a range of disease areas. He was a senior consultant at the York Health Economics Consortium at the University of York, leading projects for the National Institute for Health and Care Excellence, Department of Health, Patient Safety and Research Portfolio, and General Medical Council. Matt has a PhD in health sciences in HTA from the University of York, MSc in economics and BSc honors in economics from the University of Warwick.